Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

Tolvaptan

Availability of ACE Drug Guidance

Yes

Biologics Drug Information Overview

No

Post-marketing information

Dear Healthcare Professional Letters

Patient Medication Guide

Subsidy Information and Financing Scheme

No

Active ingredient: Tolvaptan

General information

Subsidy Information and Financing Scheme

Not Applicable

Drug Guidance for Subsidy

04/06/2024 Tolvaptan for treating autosomal dominant polycystic kidney disease (opens in new tab)

[NR] The Ministry of Health’s Drug Advisory Committee has not recommended tolvaptan for inclusion on the MOH List of Subsidised Drugs for treating autosomal dominant polycystic kidney disease (ADPKD). The decision was based on the uncertain extent of clinical benefit, and because tolvaptan was unlikely to represent a cost-effective use of healthcare resources for treating ADPKD.

View legend

Post Marketing Information

DHCPL 15/09/2025 Important update on the Risk Management Plan of Jinarc® (tolvaptan) (opens in new tab)

DHCPL 04/11/2022 Jinarc® (Tolvaptan) – New drug for treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Risk of Liver Injury (opens in new tab)

PMG 23/09/2022 Patient Education Brochure: JINARC® tolvaptan (opens in new tab)

View legend

General Availability in Public Healthcare Institution

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals (opens in new tab) or Polyclinics (opens in new tab) for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration

Availability information

Formulation

Public Healthcare Institution

Tablet 15 mg

  1. Changi General Hospital

  2. National Heart Centre

  3. National University Hospital

  4. Sengkang General Hospital

  5. Singapore General Hospital

  6. Tan Tock Seng Hospital

Tablet Tolvaptan 15 mg & Tolvaptan 45 mg

  1. Singapore General Hospital

Tablet Tolvaptan 30 mg & Tolvaptan 60 mg

  1. Singapore General Hospital

Tablet Tolvaptan 30 mg & Tolvaptan 90 mg

  1. Singapore General Hospital

Registered Product(s) Information

Clinical and product info

Clinical info

Product Info

Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch (opens in new tab).

The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice.

Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch (opens in new tab) for the most updated product information.

Oral

* Clinical information is available for this product.